All In Biotech

Drug Trial Radar · NCT06966804

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Efficacy of Alpha Blockers (Terazosin vs Tamsulosin) in Reducing Ureteral Stent Related Symptoms - An Open-label, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

May 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Penang Hospital, MalaysiaGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare how well Terazosin, Tamsulosin and standard care (no alpha-blocker) reduce urinary symptoms after ureteral stent placement. This trial also learn about the safety of these two study medications. Main objective: • To compare how well Terazosin, Tamsulosin and standard of care reduce post-stenting urinary symptoms. Secondary objectives: * To assess differences in Body pain, General health, Work performance, Sexual matters, and Additional problems using a questionnaire (USSQ). * To assess differences in side effects. After stent placement, subjects will be randomly assigned to one of three groups: 1. Terazosin (alpha-blocker) for 14 days 2. Tamsulosin (alpha-blocker) for 14 days 3. Standard of care (no alpha-blocker). All subjects will be discharged with standard pain-killers and a diary to track usage. Subjects in Terazosin and Tamsulosin groups will receive respective study medications to complete 14 days course of treatment. Follow-Up: * Day 7: A phone call will check medication use and any side effects. * Day 15: Clinic visit for stent removal (standard practice). Subjects will complete the USSQ questionnaire, and medication compliance will be reviewed. End of study: Final phone call to check for any additional side effects.

Conditions

  • Stent Related Symptoms

Interventions

  • TerazosinDrug

    Subject will complete 14-day course of Terazosin

  • TamsulosinDrug

    Subject will complete 14-day course of Tamsulosin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the efficacy of Terazosin, Tamsulosin and standard of care in reducing post-stenting urinary symptomsTime frame: From randomization to the end of the treatment at 14 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sultanah Bahiyah Hospital, Alor Setar

    Alor Star, Kedah, Malaysia · Recruiting

  • Hospital Pulau Pinang

    George Town, Pulau Pinang, Malaysia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.